BioCryst Pharmaceuticals, Inc. (BCRX) Misses Q2 EPS by 11c
Tweet Send to a FriendGet Alerts BCRX Hot Sheet
Price: $1.59 -4.22%
Revenue Growth %: -70.5%
Financial Fact:
Interest and other income: 33K
Today's EPS Names:
ANF, DXLG, FL, More
Revenue Growth %: -70.5%
Financial Fact:
Interest and other income: 33K
Today's EPS Names:
ANF, DXLG, FL, More
Trade BCRX Now!
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $8.04 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Shoe Carnival, Inc. (SCVL) Tops Q1 EPS by 6c, Guides Q2 In-Line
- Childrens Place (PLCE) Tops Q1 EPS by 22c; Boosts Outlook
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
